The project for objective measures using computational psychiatry technology (PROMPT): Rationale, design, and methodology.

Autor:	Kishimoto T; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Takamiya A; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Liang KC; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Funaki K; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Fujita T; Department of Health Policy and Management, Keio University, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Kitazawa M; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Yoshimura M; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Tazawa Y; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Horigome T; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Eguchi Y; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Kikuchi T; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan., Tomita M; Oizumi Hospital, 6-9-1 Oizumi-gakuencho, Nerimaku, Tokyo, 178-0061, Japan., Bun S; Sato Hospital, 948-1 Kunugutsuka, Nanyo, Yamagata, 999-2221, Japan., Murakami J; Biwako Hospital, 1-8-5 Sakamoto, Otsu, Shiga, 520-0113, Japan., Sumali B; Department of System Design Engineering, Keio University, 3-14-1 Hiyoshi, Minato-kita, Yokohama, Kanagawa, 223-0061, Japan., Warnita T; Department of Computer Science, School of Computing, Tokyo Institute of Technology, 4259 Nagatsuda, Yokohama, Kanagawa, 226-8503, Japan., Kishi A; Department of System Design Engineering, Keio University, 3-14-1 Hiyoshi, Minato-kita, Yokohama, Kanagawa, 223-0061, Japan., Yotsui M; Department of Biosciences and Informatics, Keio University, 3-14-1 Hiyoshi, Minato-kita, Yokohama, Kanagawa, 223-0061, Japan., Toyoshiba H; Center for Systems Medicine, Keio University, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.; FRONTEO, Inc., 2-12-23 Minato-Minami, Minato, Tokyo, 108-0075, Japan., Mitsukura Y; Department of System Design Engineering, Keio University, 3-14-1 Hiyoshi, Minato-kita, Yokohama, Kanagawa, 223-0061, Japan., Shinoda K; Department of Computer Science, School of Computing, Tokyo Institute of Technology, 4259 Nagatsuda, Yokohama, Kanagawa, 226-8503, Japan., Sakakibara Y; Department of Biosciences and Informatics, Keio University, 3-14-1 Hiyoshi, Minato-kita, Yokohama, Kanagawa, 223-0061, Japan., Mimura M; Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
Jazyk:	angličtina
Zdroj:	Contemporary clinical trials communications [Contemp Clin Trials Commun] 2020 Aug 18; Vol. 19, pp. 100649. Date of Electronic Publication: 2020 Aug 18 (Print Publication: 2020).
DOI:	10.1016/j.conctc.2020.100649
Abstrakt:	Introduction: Depressive and neurocognitive disorders are debilitating conditions that account for the leading causes of years lived with disability worldwide. However, there are no biomarkers that are objective or easy-to-obtain in daily clinical practice, which leads to difficulties in assessing treatment response and developing new drugs. New technology allows quantification of features that clinicians perceive as reflective of disorder severity, such as facial expressions, phonic/speech information, body motion, daily activity, and sleep. Methods: Major depressive disorder, bipolar disorder, and major and minor neurocognitive disorders as well as healthy controls are recruited for the study. A psychiatrist/psychologist conducts conversational 10-min interviews with participants ≤10 times within up to five years of follow-up. Interviews are recorded using RGB and infrared cameras, and an array microphone. As an option, participants are asked to wear wrist-band type devices during the observational period. Various software is used to process the raw video, voice, infrared, and wearable device data. A machine learning approach is used to predict the presence of symptoms, severity, and the improvement/deterioration of symptoms. Discussion: The overall goal of this proposed study, the Project for Objective Measures Using Computational Psychiatry Technology (PROMPT), is to develop objective, noninvasive, and easy-to-use biomarkers for assessing the severity of depressive and neurocognitive disorders in the hopes of guiding decision-making in clinical settings as well as reducing the risk of clinical trial failure. Challenges may include the large variability of samples, which makes it difficult to extract the features that commonly reflect disorder severity. Trial Registration: UMIN000021396, University Hospital Medical Information Network (UMIN). Competing Interests: T. Kishimoto has received consultant fees from Otsuka, Pfizer, and Dainippon Sumitomo, and speaker's honoraria from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer. KF has received speaker's honoraria from Novartis and Otsuka. HT is an employee of FRONTEO. TH received speaker's honoraria from Yoishitomi. T. Kikuchi has received speaker's honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, Janssen, MSD, Otsuka, Yoshitomi Yakuhin, Pfizer, and Takeda. JM has received speaker's honoraria from Eli Lilly, Janssen, Otsuka, MSD, Shionogi, and Pfizer. MM has received speaker's honoraria from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin. Also, he received grants from Daiichi Sankyo, Eisai, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi, and Tsumura. Other authors have no conflict of interest. (© 2020 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu